Archive - March 2021
New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease
Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer
Pfizer launches early study of COVID-19 antiviral therapeutic
Report urges pharma companies to utilise synthetic data in clinical trials
Zealand Pharma’s hypoglycaemia therapy Zegalogue scores approval in the US
AZ to issue primary analysis for COVID-19 vaccine following ‘outdated information’ concerns
W2O rebrands as ‘health innovation company’ Real Chemistry
FDA refuses Novo Nordisk’s once-weekly semaglutide